I

IX Biopharma Ltd
SGX:42C

Watchlist Manager
IX Biopharma Ltd
SGX:42C
Watchlist
Price: 0.017 SGD Market Closed
Market Cap: 15.1m SGD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one 42C stock under the Base Case scenario is 0.029 SGD. Compared to the current market price of 0.017 SGD, IX Biopharma Ltd is Undervalued by 42%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

42C Relative Value
Base Case
0.029 SGD
Undervaluation 42%
Relative Value
Price
I
Worst Case
Base Case
Best Case

Valuation Multiples

2.1
P/S
P/S
Price to Sales
2.1
vs History
98
vs Industry
43
Median 3Y
6
Median 5Y
9.9
Industry
2.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-3.7
Median 5Y
-14.9
Industry
20.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
36
Median 3Y
-3.5
Median 5Y
-5.3
Industry
15.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
26
Median 3Y
-3.4
Median 5Y
-5.3
Industry
23.7
More Details
4.3
P/B
P/B
Price to Book Value
4.3
vs History
82
vs Industry
13
Median 3Y
4.8
Median 5Y
5.3
Industry
2
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
98
vs Industry
41
Median 3Y
5.3
Median 5Y
9
Industry
2.6
More Details
11.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
11.6
vs History
46
vs Industry
14
Median 3Y
15
Median 5Y
10.9
Industry
5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
34
Median 3Y
-3.6
Median 5Y
-5.6
Industry
12.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
25
Median 3Y
-3.2
Median 5Y
-4.8
Industry
15.9
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
42
Median 3Y
-3.5
Median 5Y
-4.8
Industry
14.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
31
Median 3Y
-3.3
Median 5Y
-4.4
Industry
17.6
More Details
2.1
EV/IC
EV/IC
Enterprise Value to IC
2.1
vs History
92
vs Industry
28
Median 3Y
3.5
Median 5Y
7
Industry
1.8
More Details

Multiples Across Competitors

42C Competitors Multiples
IX Biopharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
SG
IX Biopharma Ltd
SGX:42C
15m SGD 2.1 -1.5 -2.4 -2.1
US
Eli Lilly and Co
NYSE:LLY
682.1B USD 13.9 61.4 33.1 36.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
367.4B USD 4.1 16.9 12.3 16.2
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.6 12.9 14.7
CH
Roche Holding AG
SIX:ROG
206.2B CHF 3.4 24.9 9.4 11
CH
Novartis AG
SIX:NOVN
181.8B CHF 4.1 17.1 10.1 13.6
UK
AstraZeneca PLC
LSE:AZN
160.9B GBP 3.9 27.8 130.6 196.9
US
Merck & Co Inc
NYSE:MRK
196.4B USD 3.1 11.3 8.4 10.2
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
116.8B EUR 1.3 9.2 5.1 6
P/E Multiple
Earnings Growth PEG
SG
I
IX Biopharma Ltd
SGX:42C
Average P/E: 23.5
Negative Multiple: -1.5 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
61.4
50%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.9
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.6
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.9
32%
0.8
CH
Novartis AG
SIX:NOVN
17.1
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.8
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.3
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.2
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SG
I
IX Biopharma Ltd
SGX:42C
Average EV/EBITDA: 433
Negative Multiple: -2.4 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.1
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
10.1
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.6
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.4
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.1
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SG
I
IX Biopharma Ltd
SGX:42C
Average EV/EBIT: 1 866.2
Negative Multiple: -2.1 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.2
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.2
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.6
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
196.9
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.2
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6
14%
0.4

See Also

Summary
42C intrinsic value, competitors valuation, and company profile.
DCF Valuation
42C stock valuation using Discount Cash Flow valuation method.
Relative Valuation
42C stock valuation using valuation multiples.
Wall Street Estimates
42C price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
42C stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 256,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.